Back to Search
Start Over
Insights into uveitis from Brentuximab vedotin in refractory Hodgkin’s lymphoma: a case report and brief review
- Source :
- Frontiers in Oncology, Vol 14 (2024)
- Publication Year :
- 2024
- Publisher :
- Frontiers Media S.A., 2024.
-
Abstract
- This case report describes a 16-year-old patient with refractory Hodgkin’s lymphoma who developed bilateral anterior and intermediate uveitis as an adverse reaction to Brentuximab vedotin (BV). This is a rare case of an ocular adverse reaction potentially related to BV, with symptoms like blurred vision, decreased visual acuity, photophobia, and redness. Potential mechanisms include BV targeting CD30+ T cells in the uveal tissue or an immune response triggered by the microtubule-disrupting agent MMAE within BV. This highlights the need for vigilant monitoring of ocular adverse events in BV-treated patients and further research into their mechanisms and management.
Details
- Language :
- English
- ISSN :
- 2234943X
- Volume :
- 14
- Database :
- Directory of Open Access Journals
- Journal :
- Frontiers in Oncology
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.7b0e025eda0340a0a107ab964e2f6c59
- Document Type :
- article
- Full Text :
- https://doi.org/10.3389/fonc.2024.1419145